90.00
0.00%
Close of 9 Nov 2026, in ZAc
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cilo Cybin Holdings
Its shares trade on JSE under the ticker CCC.JO. It has been listed since 25 June 2024. In the fiscal year to 31 March 2026, it reported revenue of ZAR 28.8m and a net loss of ZAR 239.7m. At that date it held total assets of ZAR 85.4m and shareholders' equity of ZAR 62.6m.
Cilo Cybin Holdings Ltd is a ZA-based company operating in Pharmaceuticals industry. The company is headquartered in Centurion, Gauteng. The company went IPO on 2024-06-25. Cilo Cybin Holdings Limited is a South Africa-based biotech investment company. The firm's main operations are identifying viable investments in biotech, biohacking and pharmaceutical businesses. The company is focused on supplying Good Manufacturing Practices (GMP) medical cannabis products, including GMP Cannabidiol (CBD), CBG, CBN isolates and GMP delta-9-tetrahydrocannabinol (THC), and CBD distillates. Its products include bulk products, THC distillate, CBD isolate, house brand and finished products. The company specializes in supplying medical-grade cannabis flower and final products, using a cold ethanol extraction process with input materials. The company caters to both bulk packaging and customized specifications, suitable for various applications, including vape products, oils, and edible formulations. The company also offers cannabis active pharmaceutical ingredients (API) products. Its products can be used in various applications, such as vape products, tinctures, edibles, and topicals.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 25 Jun 2024
- Website
- cilocybin.com ↗
Leadership
Pay as last reported
- Dr. Seng Kong ThamNon-Executive Chairman of the Board
- Mr. Gabriel TheronChief Executive Officer, Executive Director, since 2022
- Mr. H.B. AukampChief Financial Officer, Finance Director, Executive Director, since 2022
- Ms. Sakekile BaduzaNon-Executive Lead Independent Director
- Ms. Yoke Ling ChewNon-Executive Director
- Ms. Jessica Moodley-theronNon-Executive Director
- Ms. Lisa Eng TeohNon-Executive Director
- Mr. Mohd Razef Bin AbdullahIndependent Non-Executive Director
- Ms. Wei Sim LowIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cilo Cybin Holdings Ltd supplies GMP medical cannabis products including CBD, CBG, and THC isolates.
- The company offers GMP delta-9-tetrahydrocannabinol (THC) and CBD distillates for various applications.
- Cilo Cybin specializes in cold ethanol extraction for medical-grade cannabis flower and final products.
Weaknesses
- Cilo Cybin Holdings Ltd is a newly listed company on 25 June 2024 with limited market presence.
- The company focuses on South Africa-based operations without international expansion details.
- Cilo Cybin's business model relies on biotech investment without specified revenue streams.
Opportunities
- Cilo Cybin can expand into global medical cannabis markets beyond South Africa.
- The company may leverage GMP standards to enter the European pharmaceutical market.
- Growing demand for medical cannabis products presents opportunities for Cilo Cybin.
Threats
- Regulatory changes in South Africa could impact the medical cannabis industry.
- Competition from established pharmaceutical companies in the medical cannabis sector.
- Market volatility in the cannabis industry may affect Cilo Cybin's growth prospects.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.